On March 5, 2026, the Patented Medicine Prices Review Board (PMPRB or Board) published a series of proposed Practice Directions to streamline its hearing process. The proposed Practice Directions signal an important procedural shift away from live in-person, “action”-style hearings in favour of paper-based “application”-style hearings. This change, to facilitate shorter and less complex hearings, suggests the
Latest Post
More Posts
Health Canada proposes expediting drug approvals by relying on foreign regulatory decisions
Accelerating drug access in Canada: New pathways from the pCPA and Province of Ontario
Pharmacare update: Canada’s Drug Agency launches Appropriate Use Strategy
National Pharmacare: Canada’s Drug Agency Consulting on National Bulk Purchasing Strategy
National Pharmacare: Canada’s Drug Agency Consulting on List of Essential Prescription Drugs
Canada expanding national pharmacare and rare disease drug coverage
British Columbia becomes second province to sign pharmacare agreement
Agile licensing, risk, biologics, and more: Wide-ranging amendments to Canada’s drug and medical device regulations
National pharmacare in Canada: First-ever funding agreement announced
Subscribe: Subscribe via RSS
Firm/Org